Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstromâs macroglobulinemia (WM).
CELLECTAR BIOSCIENCES, INC. 
